GSK: Result Summaries: Compounds > fluticasone furoate

Home > Result Summaries: Compounds > fluticasone furoate

Result Summaries: fluticasone furoate

Result Summaries for fluticasone furoate
GSK Study ID	Phase	Title
100010	Phase 3	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg* and 100mcg* for 2 Weeks in Subjects Ages 2 to &lt;12 Years with Seasonal Allergic Rhinitis (SAR) (2 citation(s))
100012	Phase 3	A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of fluticasone furoateaqueous nasal spray 100mcg* QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to &lt;12 years ofage with perennial allergic rhinitis (PAR) (3 citation(s))
100650	Phase 2	Clinical Evaluation of GW685698 for Perennial Allergic Rhinitis- Dose-Finding Study by Double-Blind Comparative Method - (0 citation(s))
101747	Phase 3	A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effectof Fluticasone Furoate Nasal Spray 100mcg* Once Daily on Short-Term Growth in Children Aged 6 to 11 Years withSeasonal and/or Perennial Allergic Rhinitis (3 citation(s))
101816	Phase 3	A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg* in Adolescent and Adult Subjects (³12 years of age) with Seasonal Allergic Rhinitis (0 citation(s))
102123	Phase 3	A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis. (2 citation(s))
103096	Phase 1	A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of a new chemical entity (NCE) and inhaled fluticasone propionate (FP) on twenty-four hour serum cortisol in healthy subjects. (0 citation(s))
103184	Phase 3	A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate theEfficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* in Adultand Adolescent Subjects with Seasonal Allergic Rhinitis in Europe (3 citation(s))
104861	Phase 3	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacyand Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 2 Weeks inAdult and Adolescent Subjects =12 Years of Age with Seasonal Allergic Rhinitis (3 citation(s))
106080	Phase 3	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy andSafety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 6 Weeks in Adultand Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhin ... (2 citation(s))
108556	Phase 3	Study FFU108556, A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and FluticasonePropionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis (1 citation(s))
112018	phase 1	Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects. (0 citation(s))
112185	phase 4	A phase-IV, open-label study to evaluate safety/tolerability of once-daily AVAMYS (TM) aqueous nasal spray 110mcg among Vietnamese adult patients with established perennial allergic rhinitis (PAR) (0 citation(s))
112202	Phase 2	A Multi-Centre, Randomized, Double Blind Cross-over study to assess the non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients with Asthma (0 citation(s))
FFA10022	Phase 1	A randomised, double-blind, placebo-controlled, incomplete block, 3-way cross-over study to investigate the effect of repeat inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) in mild asthmatic patients (0 citation(s))
FFA10027	Phase 1	A randomised, double-blind, placebo-controlled, 6-way cross-over design study to investigate the effect of 250 µg single inhaled doses of GW685698X and FP on airway responsiveness to adenosine 5’-monophosphate (AMP) challenge in mild asthmatic patients (0 citation(s))
FFA10028	Phase 1	A randomised, double-blind, placebo-controlled, balanced incomplete block, multiple dose crossover study to investigate the effect of 3 Days repeat dosing of GW685698X and fluticasone propionate (1000 µg) on exhaled nitric oxide in mild to moderate asthmatic patients. (0 citation(s))
FFA109684	Phase 2	See Detailed Description (0 citation(s))
FFA109685	Phase 2	See Detailed Description (0 citation(s))
FFA109687	phase 2	See Detailed Description (0 citation(s))
FFR10005	Phase 1	A double blind, randomised, placebo-controlled, single and multiple intranasal dose study to investigate the safety, tolerability and pharmacokinetics of GW685698 in Japanese healthy male subject. (0 citation(s))
FFR100652	Phase 3	Clinical Evaluation of GW685698 for Seasonal Allergic Rhinitis -A Placebo-controlled Study to Determine the Non-inferiority of GW685698 over Fluticasone Propionate Using a Double-blind Manner- (0 citation(s))
FFR100688	Phase 3	Study of Perennial Allergic Rhinitis -Long term treatment study- (0 citation(s))
FFR104503	Phase 3	See Detailed Description (1 citation(s))
FFR105693	Phase 3	A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience with Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects with Seasonal Allergic Rhinitis during a Three-week Cross-over Study (0 citation(s))
FFR111158	Phase 2	A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents with Irritant (Non-Allergic) Rhinitis (0 citation(s))
FFR20001	Phase 2	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg, 100mcg, 200mcg, or 400mcg for 14 days in Adult and Adolescent Subjects with SARs. (4 citation(s))
FFR20002	Phase 3	See Detailed Description (2 citation(s))
FFR30002	Phase 3	See Detailed Description (1 citation(s))
FFR30003	phase 3	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis (4 citation(s))
FFR30006	Phase 3	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis (0 citation(s))
FFR30007	Phase 3	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis (0 citation(s))
FFR30008	Phase 3	See Detailed Description (3 citation(s))
FFU104503	Phase 3	A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg* QD via Nasal Biopsy in Subjects >/18 Years of Age with Perennial Allergic Rhinitis (PAR (1 citation(s))
FFU105924	Phase 4	R, DB, PC, AC, One-Week, Cross-Over, MC Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg FFNS and 200mcg FPNS in Adult Subjects with SAR (0 citation(s))
FFU105927	Phase 4	R, DB, PC, AC, One-Week, Cross-Over, MCStudy to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcgFluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhiniti (0 citation(s))
FFU109045	Phase 4	A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis (4 citation(s))
FFU109047	Phase 4	A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis (0 citation(s))
FFU111439	Phase 4	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR) (0 citation(s))

Result Summaries: fluticasone furoate

Filter list by: